Board of Governors of the Federal Reserve System, August 23, 1996.

Jennifer J. Johnson

Deputy Secretary of the Board

[FR Doc. 96–21949 Filed 8-27-96; 8:45 am]

BILLING CODE 6210-01-F

### Notice of Proposals to Engage in Permissible Nonbanking Activities or to Acquire Companies that are Engaged in Permissible Nonbanking Activities

The companies listed in this notice have given notice under section 4 of the Bank Holding Company Act (12 U.S.C. 1843) (BHC Act) and Regulation Y, (12 CFR Part 225) to engage de novo, or to acquire or control voting securities or assets of a company that engages either directly or through a subsidiary or other company, in a nonbanking activity that is listed in § 225.25 of Regulation Y (12 CFR 225.25) or that the Board has determined by Order to be closely related to banking and permissible for bank holding companies. Unless otherwise noted, these activities will be conducted throughout the United States.

Each notice is available for inspection at the Federal Reserve Bank indicated. Once the notice has been accepted for processing, it will also be available for inspection at the offices of the Board of Governors. Interested persons may express their views in writing on the question whether the proposal complies with the standards of section 4 of the BHC Act, including whether consummation of the proposal can "reasonably be expected to produce benefits to the public, such as greater convenience, increased competition, or gains in efficiency, that outweigh possible adverse effects, such as undue concentration of resources, decreased or unfair competition, conflicts of interests, or unsound banking practices" (12 U.S.C. 1843). Any request for a hearing on this question must be accompanied by a statement of the reasons a written presentation would not suffice in lieu of a hearing, identifying specifically any questions of fact that are in dispute, summarizing the evidence that would be presented at a hearing, and indicating how the party commenting would be aggrieved by approval of the proposal.

Unless otherwise noted, comments regarding the applications must be received at the Reserve Bank indicated or the offices of the Board of Governors not later than September 12, 1996.

A. Federal Reserve Bank of Kansas City (John E. Yorke, Senior Vice President) 925 Grand Avenue, Kansas City, Missouri 64198: 1. Bankers Bancorp of Oklahoma, Inc., Oklahoma City, Oklahoma; to engage de novo in a joint venture through its subsidiary, Bankers Bank Systems, Oklahoma City, Oklahoma, in data processing activities, pursuant to § 225.25(b)(7) of the Board's Regulation Y.

Board of Governors of the Federal Reserve System, August 23, 1996. Jennifer J. Johnson Deputy Secretary of the Board [FR Doc. 96–21948 Filed 8-27-96; 8:45 am] BILLING CODE 6210-01-F

### Sunshine Act Meeting

**AGENCY HOLDING THE MEETING:** Board of Governors of the Federal Reserve System

TIME AND DATE: 11:00 a.m., Tuesday, September 3, 1996.

PLACE: Marriner S. Eccles Federal Reserve Board Building, C Street entrance between 20th and 21st Streets, N.W., Washington, D.C. 20551. STATUS: Closed.

#### MATTERS TO BE CONSIDERED:

1. Personnel actions (appointments, promotions, assignments, reassignments, and salary actions) involving individual Federal Reserve System employees.

2. Any items carried forward from a previously announced meeting.

CONTACT PERSON FOR MORE INFORMATION: Mr. Joseph R. Coyne, Assistant to the Board; (202) 452–3204. You may call (202) 452–3207, beginning at approximately 5 p.m. two business days before this meeting, for a recorded announcement of bank and bank holding company applications scheduled for the meeting.

Dated: August 26, 1996.
William W. Wiles,
Secretary of the Board.
[FR Doc. 96–22052 Filed 8–26–96; 10:59 am]
BILLING CODE 6210–01–P

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

# Centers for Disease Control and Prevention

National Vaccine Advisory Committee (NVAC), Subcommittee on Vaccine Safety, Subcommittee on Immunization Coverage, Subcommittee on Future Vaccines, and the Advisory Commission on Childhood Vaccines (ACCV), Subcommittee on Vaccine Safety: Meetings

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92–463), the Centers for Disease Control and Prevention (CDC) announces the following Federal advisory committee meetings.

*Name:* National Vaccine Advisory Committee (NVAC).

Times and Dates: 9 a.m.-1:30 p.m., September 9, 1996. 8:30 a.m.-12:30 p.m., September 10, 1996.

Place: Hubert H. Humphrey Building, Room 702A, 200 Independence Avenue, SW, Washington, DC 20201.

*Status*: Open to the public, limited only by the space available.

Notice: In the interest of security, the Department has instituted stringent procedures for entrance to the Hubert H. Humphrey Building by non-government employees. Thus, persons without a government identification card should plan to arrive at the building each day either between 8 and 8:30 a.m. or 12:30 and 1 p.m. so they can be escorted to the meeting. Entrance to the meeting at other times during the day cannot be assured.

Purpose: The Committee shall advise and make recommendations to the Director of the National Vaccine Program on matters related

to the Program responsibilities.

Matters to be Discussed: The Committee will receive reports on the status of NVAC nominees to replace members whose terms have ended, status of new exofficio members from the Department of Agriculture and the Health Care Financing Administration, and a discussion regarding the addition of liaison representatives to the Committee; the recruitment status for the Director, National Vaccine Program Office (NVPO); update alternatives for adverse event surveillance and funding options; update immunization registry: confidentiality issues; NVAC endorsement of the immunization information system confidentiality paper; update philosophical exemption to immunization; the Measles Vaccine Timing Study—Discussion of Edmonston-Zagreb (EZ) Vaccine Study; Institutes of Medicine risk communication safety forum; an update on the Subcommittee on Immunization Coverage Draft Papers, Thirteen Points of Leverage to Increase Coverage and Access to Immunization; an update on the Subcommittee on Future Vaccines, vaccine research partnership, and a status report on Sabin case studies; an update on the Subcommittee on Vaccine Safety; update on Adult Immunization Work Group; report on children's vaccine initiative; update on the National Vaccine Injury Compensation Program, a report from the Task Force on Safer Vaccines, a review of adverse events litigation and compensation in adults; and an update on Acellular Pertussis.

Agenda items are subject to change as priorities dictate.

Name: NVAC Subcommittee on Vaccine Safety and the ACCV, Subcommittee on Vaccine Safety.

*Time and Date:* 1:30 p.m.–5 p.m., September 9, 1996.

*Place:* Hubert H. Humphrey Building, Room 425A, 200 Independence Avenue, SW, Washington, DC 20201.

*Status*: Open to the public, limited only by the space available.

*Purpose:* This joint ACCV/NVAC subcommittee will review issues relevant to